首页> 美国卫生研究院文献>Journal of Cardiovascular Ultrasound >Transient Use of Oral Bosentan Can Be an Additional Option to Reduce Pulmonary Arterial Hypertension in a Patient with Severe Pulmonary Arterial Hypertension Associated with Atrial Septal Defect
【2h】

Transient Use of Oral Bosentan Can Be an Additional Option to Reduce Pulmonary Arterial Hypertension in a Patient with Severe Pulmonary Arterial Hypertension Associated with Atrial Septal Defect

机译:短暂使用口服波生坦可能是减轻患有房间隔缺损的重度肺动脉高压患者肺动脉高压的另一种选择

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Atrial septal defect (ASD) with severe pulmonary arterial hypertension (PAH) is thought to preclude shunt closure. However, there are several reports that vasodilator treatment is associated with good clinical outcome in these patients, recently. We report a case of good clinical outcome in a patient with ASD and severe PAH successfully treated with operative closure of ASD and subsequent use of oral bosentan medication. This case supports that the corrective repair of ASD and an oral bosentan treatment can be one of the treatment options in the selected patients with severe PAH associated with ASD.
机译:房间隔缺损(ASD)伴有严重的肺动脉高压(PAH)被认为可避免分流闭合。但是,最近有几篇报道说血管扩张剂治疗与这些患者的良好临床结局有关。我们报告了在ASD和重度PAH患者中成功手术闭合ASD并随后使用口服波生坦药物成功治疗的良好临床结果。该病例支持对患有严重自发性肺动脉高压并伴有自发性肺动脉高压的特定患者,ASD的纠正修复和口服波生坦治疗可以作为治疗选择之一。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号